- Home
- SNY vs IOVA Comparison
SNY vs IOVA Comparison
Compare SNY & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNY
- IOVA
- Stock Information
- Founded
- SNY 1994
- IOVA 2007
- Country
- SNY France
- IOVA United States
- Employees
- SNY N/A
- IOVA N/A
- Industry
- SNY Biotechnology: Pharmaceutical Preparations
- IOVA Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNY Health Care
- IOVA Health Care
- Exchange
- SNY Nasdaq
- IOVA Nasdaq
- Market Cap
- SNY 123.6B
- IOVA N/A
- IPO Year
- SNY N/A
- IOVA N/A
- Fundamental
- Price
- SNY $53.63
- IOVA $3.51
- Analyst Decision
- SNY Buy
- IOVA Strong Buy
- Analyst Count
- SNY 2
- IOVA 9
- Target Price
- SNY $62.50
- IOVA $18.22
- AVG Volume (30 Days)
- SNY 3.6M
- IOVA 9.9M
- Earning Date
- SNY 04-24-2025
- IOVA 05-08-2025
- Dividend Yield
- SNY 3.08%
- IOVA N/A
- EPS Growth
- SNY 39.56
- IOVA N/A
- EPS
- SNY 5.45
- IOVA N/A
- Revenue
- SNY $48,817,552,946.00
- IOVA $164,070,000.00
- Revenue This Year
- SNY $5.35
- IOVA $182.20
- Revenue Next Year
- SNY $6.69
- IOVA $62.10
- P/E Ratio
- SNY $9.60
- IOVA N/A
- Revenue Growth
- SNY N/A
- IOVA 13698.99
- 52 Week Low
- SNY $45.80
- IOVA $2.70
- 52 Week High
- SNY $60.12
- IOVA $14.23
- Technical
- Relative Strength Index (RSI)
- SNY 50.20
- IOVA 51.94
- Support Level
- SNY $50.46
- IOVA $2.89
- Resistance Level
- SNY $51.64
- IOVA $3.43
- Average True Range (ATR)
- SNY 1.60
- IOVA 0.32
- MACD
- SNY 0.15
- IOVA 0.09
- Stochastic Oscillator
- SNY 65.92
- IOVA 86.17
About SNY Sanofi ADS
Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.